Chronic uveitis treated with specific biological drug treatment should group to 808H in the Norwegian version
|Target version:||Target version 2021|
|Case type:||Minor||Owner / responsible:||National organisations|
|MDC:||MDC08||Old forum status:|
This problem has been reported from Helse Møre og Romsdal HF. When patients are treated with biological drug treatment for isolated uveitis (e.g. children / adolescents who do not have arthritis or other known autoimmune conditions) they are treated by the eye departments. Nationally, for more than 10 years, Infliximab has been a recognized treatment for these patients if the condition is not controlled through other treatment modalities. Indication for such treatment in children is clarified with a pediatric rheumatologist at the regional hospital.
These cases with ICD-10 code H201 'Kronisk Uveitt/Chronic uveitis' and procedure code 4AB02 'Treatment with L04AB02 Infliximab' + WBGM00 'Intravenous drug treatment' now groups to DRG 902O 'Poliklinisk konsultasjon vedrørende andre øyesykdommer /Outpatient consultation regarding other eye diseases'. Because of the specific biological drug treatment it would be more correct that these cases should be grouped to DRG 808H 'Poliklinisk behandling av revmatologiske lidelser med infusjon av særskilte legemidler/ Outpatient treatment of rheumatological disorders with infusion of special medicines'.
The DRG-logic in the Norwegian version is changed accordingly by adding two new rules and giving ICD-10 code H201 two new properties. This only affects the Norwegian version because of our inclusion of drug treatment codes in the DRG-logic, and further details and analysis is therefore not presented here. Technical specification added.